ONCOCROSS

  • ONCOCROSS

    • Mission

    • History

    • Leadership

    • Scientific Advisory Board

  • Technology

    • Platform

    • ONCOCROSS AI Platform

      • RAPTOR AI™

      • ONCO-RAPTOR AI™

      • ONCOfind AI™

    • in vitro / in vivo analysis

  • Collaboration

    • New Indication

    • Optimal Cancer Type Identification

    • CUP Primary Site Identification

  • News/IR

    • Announcement

    • Press

    • Regulatory Disclosure

    • Stock Information

CONTACT US
한
  • ONCOCROSS

    • Mission

    • History

    • Leadership

    • Scientific Advisory Board

  • Technology

    • Platform

    • ONCOCROSS AI Platform

      • RAPTOR AI™

      • ONCO-RAPTOR AI™

      • ONCOfind AI™

    • in vitro / in vivo analysis

  • Collaboration

    • New Indication

    • Optimal Cancer Type Identification

    • CUP Primary Site Identification

  • News/IR

    • Announcement

    • Press

    • Regulatory Disclosure

    • Stock Information

  • 한
  • EN
CONTACT US
  • Main
  • News/IR
  • Press

PAX경제TV

코스닥 상장 앞둔 '온코크로스', 의사출신의 '전문성' 바탕으로 AI신약 '적응증 확장' 돕는다

  • 12-04-2024
https://www.paxetv.com/news/articleView.html?idxno=218294
Previous
(주)온코크로스 코스닥시장 상장기념식 12-18-2024
Next
김이랑 온코크로스 대표 "신약 후보 발굴 넘어 진단까지…AI 신약 경쟁력 자신" 11-21-2024
List

Please enter a prompt

ONCOCROSS
CEO
Yi Rang KIM / Jihoon KANG
Address
#905 7 Beobwon-ro 11-gil, Songpa-gu, Seoul, 05836, Korea
Tel
02-717-9967
Fax
02-867-9968
Email
oncocross@oncocross.com
Terms & Conditions Privacy Policy Cookie Policy
ⓒ ONCOCROSS CO., LTD. All Rights Reserved.